Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Once again, rare diseases provide a spotlight.

Literature DB >> 27017192

Once again, rare diseases provide a spotlight.

Tamanna Roshan Lal¹, Daniel K Borger¹, Ellen Sidransky².

Abstract

Entities: Chemical Disease Gene Species

Keywords: Gaucher disease; Lysolipids; Monoclonal gammopathy; Multiple myeloma

Mesh：

Substances：
Lysophosphatidylcholines

Year: 2016 PMID： 27017192 PMCID： PMC5446090 DOI： 10.1016/j.ymgme.2016.03.002

Source DB: PubMed Journal: Mol Genet Metab ISSN： 1096-7192 Impact factor: 4.797

Keyword Cloud
References

× No keyword cloud information.

13 in total

1. Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher's disease.

Authors: J Deibener; P Kaminsky; C Jacob; B Dousset; M Klein; M Duc
Journal: Haematologica Date: 1998-05 Impact factor: 9.941

2. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.

Authors: Pramod K Mistry; Elena Lukina; Hadhami Ben Turkia; Dominick Amato; Hagit Baris; Majed Dasouki; Marwan Ghosn; Atul Mehta; Seymour Packman; Gregory Pastores; Milan Petakov; Sarit Assouline; Manisha Balwani; Sumita Danda; Evgueniy Hadjiev; Andres Ortega; Suma Shankar; Maria Helena Solano; Leorah Ross; Jennifer Angell; M Judith Peterschmitt
Journal: JAMA Date: 2015-02-17 Impact factor: 56.272

3. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response.

Authors: Nick Dekker; Laura van Dussen; Carla E M Hollak; Herman Overkleeft; Saskia Scheij; Karen Ghauharali; Mariëlle J van Breemen; Maria J Ferraz; Johanna E M Groener; Mario Maas; Frits A Wijburg; Dave Speijer; Anna Tylki-Szymanska; Pramod K Mistry; Rolf G Boot; Johannes M Aerts
Journal: Blood Date: 2011-08-25 Impact factor: 22.113

8. Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy.

Authors: Neal J Weinreb; Robert E Lee
Journal: Crit Rev Oncog Date: 2013

Review 9. Gaucher disease and myeloma.

Authors: Robert Ayto; Derralynn A Hughes
Journal: Crit Rev Oncog Date: 2013

Review 10. Gaucher disease and comorbidities: B-cell malignancy and parkinsonism.

Authors: Timothy M Cox; Barry E Rosenbloom; Roger A Barker
Journal: Am J Hematol Date: 2015-07 Impact factor: 10.047

Once again, rare diseases provide a spotlight.

1. Enzyme replacement therapy decreases hypergammaglobulinemia in Gaucher's disease.

2. Effect of oral eliglustat on splenomegaly in patients with Gaucher disease type 1: the ENGAGE randomized clinical trial.

3. Elevated plasma glucosylsphingosine in Gaucher disease: relation to phenotype, storage cell markers, and therapeutic response.

Review 4. Heterozygosity for a Mendelian disorder as a risk factor for complex disease.

5. Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma.

Review 6. Malignancies and monoclonal gammopathy in Gaucher disease; a systematic review of the literature.

Review 7. Glucocerebrosidase is shaking up the synucleinopathies.

8. Causes of death due to hematological and non-hematological cancers in 57 US patients with type 1 Gaucher Disease who were never treated with enzyme replacement therapy.

Review 9. Gaucher disease and myeloma.

Review 10. Gaucher disease and comorbidities: B-cell malignancy and parkinsonism.